Latest News about LGND
Recent news which mentions LGND
   Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
   
  
  
  November 28, 2023
  From Benzinga
 
   Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
   
  September 19, 2023
  Tickers 
   LGND
  
  
  From Benzinga
 
   Why Are Novan Shares Nosediving Today?
   
  
  
  July 17, 2023
  From Benzinga
 From InvestorPlace
 
   Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
   
  
  
  May 16, 2023
  From Benzinga
 
   Earnings Scheduled For February 22, 2023
   
  
  
  February 22, 2023
  From Benzinga
 
   Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
   
  
  
  February 21, 2023
  From Benzinga
 From Benzinga
 
   Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
   
  December 23, 2022
  Tickers 
   LGND
  
  
  From Benzinga
 
   Tesla To $175? Here Are 10 Other Price Target Changes For Friday
   
  
  
  December 23, 2022
  From Benzinga
 
   Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
   
  
  
  December 16, 2022
  From Benzinga
 
   Best stock picks for 2023: Here are Wall Street analysts’ most heavily favored choices
   
  
  
  December 13, 2022
  From MarketWatch
 
   These small-cap stocks might make you the most money in 2023, based on two important data points
   
  
  
  December 07, 2022
  From MarketWatch
 
   12 Health Care Stocks Moving In Wednesday's Pre-Market Session
   
  
  
  November 02, 2022
  From Benzinga
 
   Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
   
  
  
  November 01, 2022
  From Benzinga
 
   Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
   
  
  
  August 25, 2022
  From Benzinga
 
   Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
   
  
  
  August 24, 2022
  From Benzinga
 
   Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know
   
  July 05, 2022
  Tickers 
   LGND
  
  
  From Benzinga
 
   ASCO 2022: Surprising News in Cancer Research
   
  
  
  June 10, 2022
  From Motley Fool
 
   10 Biggest Price Target Changes For Monday
   
  
  
  May 16, 2022
  From Benzinga
 From Benzinga
 From Benzinga
 
   Stocks That Hit 52-Week Lows On Wednesday
   
  
  
  February 23, 2022
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
